Vimarsana
Biggest News Aggregation in the World

V Bio Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from V Bio Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In V Bio Ventures Today - Breaking & Trending Today

Funding steers Cardiovascular Pipeline towards Clinical Entry - Vimarsana News

Funding steers Cardiovascular Pipeline towards Clinical Entry

Biopharma Corteria, which announced an oversubscribed €65M ($71M) Series A co-led by investment firms OrbiMed (US) and Jeito Capital (EU), will be  using the funding to advance its cardiovascular pipeline into the clinic. Click to read more...

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardi - Vimarsana News

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardi

Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a ... - Vimarsana News

Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a ...

Jeito Capital co-leads EUR 65 million (USD 711M) financing in

Corteria Pharmaceuticals Raises €65M in Series A Funding - Vimarsana News

Corteria Pharmaceuticals Raises €65M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

AstriVax Awarded €2.5 Million Grant to Advance Innovative - Vimarsana News

AstriVax Awarded €2.5 Million Grant to Advance Innovative

The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the company’s vaccine platform....